Q-omics provides the consensus-scored DHRS7 profile across patient tissues and cancer cell-line models. DHRS7 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, DHRS7 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, DHRS7 protein abundance shows 22,167 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where DHRS7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DHRS7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DHRS7 survival associations across molecular data types. DHRS7 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DHRS7 RNA expression–survival associations across cancer types. High DHRS7 expression shows unfavorable associations in HNSC, UVM and STAD, but favorable associations in BRCA, KIRC and MESO. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for DHRS7 RNA expression.
This table summarizes DHRS7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for DHRS7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DHRS7 shows lower tumor expression in KIRC, THCA and LUSC and higher tumor expression in KICH, HNSC and LIHC. The KIRC box plot shows higher DHRS7 RNA expression in normal versus tumor tissue (log2 FC = −0.768, t-test p < 0.001).
This table shows molecular features associated with DHRS7 in patient tissues and cancer cell lines. In patient samples, DHRS7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, DHRS7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
